Voyager Therapeutics, Inc. (VYGR)

NASDAQ: VYGR · IEX Real-Time Price · USD
5.98
-0.04 (-0.66%)
Aug 16, 2022 11:39 AM EDT - Market open
-0.66%
Market Cap 231.11M
Revenue (ttm) 30.93M
Net Income (ttm) -59.83M
Shares Out 38.65M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,738
Open 6.08
Previous Close 6.02
Day's Range 5.86 - 6.10
52-Week Range 2.46 - 10.60
Beta 1.08
Analysts Buy
Price Target 6.73 (+12.5%)
Earnings Date Aug 8, 2022

About VYGR

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear p... [Read more...]

Industry Biotechnology
IPO Date Nov 11, 2015
CEO G. Andre Turenne
Employees 101
Stock Exchange NASDAQ
Ticker Symbol VYGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 6.73, which is an increase of 12.54% from the latest price.

Price Target
$6.73
(12.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Voyager customer lost $1 million saved over 24 years and is one of many now desperate to recoup funds

Voyager Digital had 3.5 million customers, and many are now doing everything they can to try and get some of their money back.

Sam Bankman-Fried's crypto firms had deep ties to Voyager Digital and its bankruptcy wipeout

Court proceedings and financial documents detail how complicated relationships were between the two Bankman-Fried firms — Alameda and FTX — and Voyager Digital.

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in ...

Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-assoc...

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D.

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV)...

Voyager Therapeutics' TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results B...

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Deri...

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™  AAV9- and AAV5-derived ...

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annu...

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) ...

Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last?

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea...

Voyager Therapeutics (VYGR) Is Up 21.18% in One Week: What You Should Know

Does Voyager Therapeutics (VYGR) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 Nasdaq Stocks That Have Soared 132% to 1,278% This Year

Are these high-flying stocks smart picks to buy now?

Other symbols: SKYXTLMD

Voyager names former Biogen executive Alfred Sandrock as CEO

Shares of Voyager Therapeutics Inc. VYGR, +7.45% gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. BIIB, -0.84% executive Dr. Alfred Sandrock Jr...

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D.

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy Renowned neuroscientist brings pioneering drug development expertis...

Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?

Voyager Therapeutics has promising technology. But the stock is very risky.

Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

After Golden Cross, Voyager Therapeutics (VYGR)'s Technical Outlook is Bright

Is it a good or bad thing when a stock experiences a golden cross technical event?

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

License option agreement with Novartis for target-specific access to TRACER™  next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases, with an option...

Other symbols: NVS

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation T...

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties

Will Voyager Therapeutics (VYGR) Report Negative Q4 Earnings? What You Should Know

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) ...